A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis

Critical Care Medicine

Volumn 41, Issue 3, 2013, Pages 706-716

  Guntupalli, Kalpalatha ^a   Dean, Nathan ^b   Morris, Peter E ^c   Bandi, Venkata ^a   Margolis, Benjamin ^d   Rivers, Emanuel ^e   Levy, Mitchell ^f   Lodato, Robert F ^g   Ismail, Preeti M ^h   Reese, Amber ^h   Schaumberg, John P ^h   Malik, Rajesh ^h   Dellinger, R Phillip ⁱ  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c WAKE FOREST UNIVERSITY   (United States)

^d West Suburban Medical Center   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f BROWN UNIVERSITY   (United States)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^h AGENNIX INC   (United States)

ⁱ Department of Anesthesiology   (United States)

Author keywords

Lactoferrin; Septic shock; Severe sepsis; Talactoferrin alfa

Indexed keywords

PLACEBO; TALACTOFERRIN;

ABDOMINAL INFECTION; ADULT; ANTIBIOTIC THERAPY; APACHE; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMERGENCY WARD; FEMALE; HUMAN; INTENSIVE CARE UNIT; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SEPSIS; SKIN INFECTION; SUPERINFECTION; TREATMENT DURATION; URINARY TRACT INFECTION;

ADULT; AGED; APACHE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HOSPITAL MORTALITY; HUMANS; INFUSIONS, PARENTERAL; INTENSIVE CARE UNITS; LACTOFERRIN; MALE; MIDDLE AGED; PLACEBOS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SEPSIS; TREATMENT OUTCOME;

EID: 84874886669     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3182741551     Document Type: Article

References (50)

1. Bone RC, Sibbald WJ, Sprung C L: The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992; 101:1481-1483
2. Bone RC, Balk RA, Cerra FB, et al.: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655
3. Angus DC, Linde-Zwirble WT, Lidicker J, et al.: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
4. Russell J A: Management of sepsis. N Engl J Med 2006; 355:1699-1713
5. Dellinger RP, Levy MM, Carlet JM, et al; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
6. Metz-Boutigue MH, Jollès J, Mazurier J, et al.: Human lactotransferrin: Amino acid sequence and structural comparisons with other transferrins. Eur J Biochem 1984; 145:659-676
7. Probable role of lactoferrin in the transport of iron across the intestinal brush border. Nutr Rev 1980; 38:256-257
8. Masson PL, Heremans J F: Lactoferrin in milk from different species. Comp Biochem Physiol, B 1971; 39:119-129
9. Levay PF, Viljoen M: Lactoferrin: A general review. Haematologica 1995; 80:252-267
10. Masson PL, Heremans JF, Schonne E: Lactoferrin, an iron-binding protein in neutrophilic leukocytes. J Exp Med 1969; 130:643-658
11. Ward PP, Piddington CS, Cunningham GA, et al: A system for production of commercial quantities of human lactoferrin: A broad spectrum natural antibiotic. Biotechnology (NY) 1995; 13:498-503
12. Sun XL, Baker HM, Shewry SC, et al.: Structure of recombinant human lactoferrin expressed in Aspergillus awamori. Acta Crystallogr D Biol Crystallogr 1999; 55(Pt 2):403-407
13. Miehlke S, Reddy R, Osato MS, et al.: Direct activity of recombinant human lactoferrin against Helicobacter pylori. J Clin Microbiol 1996; 34:2593-2594
14. Dial EJ, Romero JJ, Headon DR, et al.: Recombinant human lactoferrin is effective in the treatment of Helicobacter felis-infected mice. J Pharm Pharmacol 2000; 52:1541-1546
15. Edde L, Hipolito RB, Hwang FF, et al.: Lactoferrin protects neonatal rats from gut-related systemic infection. Am J Physiol Gastrointest Liver Physiol 2001; 281:G1140-G1150
16. Cumberbatch M, Dearman RJ, Uribe-Luna S, et al.: Regulation of epidermal Langerhans cell migration by lactoferrin. Immunology 2000; 100:21-28
17. Spadaro M, Caorsi C, Ceruti P, et al.: Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells. FASEB J 2008; 22:2747-2757
18. de la Rosa G, Yang D, Tewary P, et al.: Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses. J Immunol 2008; 180:6868-6876
19. Troost FJ, Saris WH, Brummer R J: Recombinant human lactoferrin ingestion attenuates indomethacin-induced enteropathy in vivo in healthy volunteers. Eur J Clin Nutr 2003; 57:1579-1585
20. Yen CC, Lin CY, Chong KY, et al.: Lactoferrin as a natural regimen for selective decontamination of the digestive tract: Recombinant porcine lactoferrin expressed in the milk of transgenic mice protects neonates from pathogenic challenge in the gastrointestinal tract. J Infect Dis 2009; 199:590-598
21. Dial EJ, Dohrman AJ, Romero JJ, et al.: Recombinant human lactoferrin prevents NSAID-induced intestinal bleeding in rodents. J Pharm Pharmacol 2005; 57:93-99
22. Kruzel ML, Harari Y, Chen CY, et al.: Lactoferrin protects gut mucosal integrity during endotoxemia induced by lipopolysaccharide in mice. Inflammation 2000; 24:33-44
23. Zimecki M, Artym J, Chodaczek G, et al.: Protective effects of lactoferrin in Escherichia coli-induced bacteremia in mice: Relationship to reduced serum TNF alpha level and increased turnover of neutrophils. Inflamm Res 2004; 53:292-296
24. Parikh PM, Vaid A, Advani SH, et al.: Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J Clin Oncol 2011; 29:4129-4136
25. Digumarti R, Wang Y, Raman G, et al: A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J Thorac Oncol 2011; 6:1098-1103
26. Jonasch E, Stadler WM, Bukowski RM, et al.: Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer 2008; 113:72-77
27. Lyons TE, Miller MS, Serena T, et al.: Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: A phase . clinical study. Am J Surg 2007; 193:49-54
28. Mojaverian P: Single and multiple dose safety, tolerability and pharmacokinetics (PK) of oral recombinant lactoferrin (rhLF) in healthy subjects. Salt Lake City, UT, Proc Ann Mtg Am Asso Pharm Scientists, 2003
29. Hayes TG, Falchook GF, Varadhachary GR, et al.: Phase I trial of oral talactoferrin alfa in refractory solid tumors. Invest New Drugs 2006; 24:233-240
30. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
31. Otero RM, Nguyen HB, Huang DT, et al.: Early goal-directed therapy in severe sepsis and septic shock revisited: Concepts, controversies, and contemporary findings. Chest 2006; 130:1579-1595
32. Rivers E, Nguyen B, Havstad S, et al; Early Goal-Directed Therapy Collaborative Group: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377
33. Anderson BF, Baker HM, Norris GE, et al.: Structure of human lactoferrin: Crystallographic structure analysis and refinement at 2.8 A resolution. J Mol Biol 1989; 209:711-734
34. Levay PF, Viljoen M: Lactoferrin: A general review. Haematologica 1995; 80:252-267
35. Sherman M P: New concepts of microbial translocation in the neonatal intestine: Mechanisms and prevention. Clin Perinatol 2010; 37:565-579
36. Hirai Y, Kawakata N, Satoh K, et al.: Concentrations of lactoferrin and iron in human milk at different stages of lactation. J Nutr Sci Vitaminol 1990; 36:531-544
37. Manzoni P, Rinaldi M, Cattani S, et al; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections, Italian Society of Neonatology: Bovine lactoferrin supplementation for prevention of lateonset sepsis in very low-birth-weight neonates: A randomized trial. JAMA 2009; 302:1421-1428
38. Håversen L, Ohlsson BG, Hahn-Zoric M, et al.: Lactoferrin downregulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. Cell Immunol 2002; 220:83-95
39. Håversen LA, Baltzer L, Dolphin G, et al.: Anti-inflammatory activities of human lactoferrin in acute dextran sulphate-induced colitis in mice. Scand J Immunol 2003; 57:2-10
40. Håversen LA, Engberg I, Baltzer L, et al.: Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infection in mice. Infect Immun 2000; 68:5816-5823
41. Raetz CR, Ulevitch RJ, Wright SD, et al.: Gram-negative endotoxin: An extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J 1991; 5:2652-2660
42. Ulevitch RJ, Tobias P S: Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995; 13:437-457
43. Pajkrt D, Doran JE, Koster F, et al.: Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184:1601-1608
44. Pastores SM, Katz DP, Kvetan V: Splanchnic ischemia and gut mucosal injury in sepsis and the multiple organ dysfunction syndrome. Am J Gastroenterol 1996; 91:1697-1710
45. Schwarz B, Salak N, Hofstötter H, et al.: Intestinal ischemic reperfusion syndrome: Pathophysiology, clinical significance, therapy. Wien Klin Wochenschr 1999; 111:539-548
46. Stallion A, Kou TD, Latifi SQ, et al.: Ischemia/reperfusion: A clinically relevant model of intestinal injury yielding systemic inflammation. J Pediatr Surg 2005; 40:470-477
47. Rice TW, Wheeler AP, Bernard GR, et al: A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 2010; 38:1685-1694
48. Bernard GR, Zeno B, Bernard AC, et al: A Randomized, Placebo-Controlled, Dose Escalation Trial of Anti-TNF (AZD9773) in patients with severe sepsis. Am J Respir Crit Care Med 2011; 183:A5604
49. Hotchkiss RS, Karl I E: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150
50. Kalil AC, LaRosa SP, Gogate J, et al; Eritoran Sepsis Study Group: Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis. Shock 2011; 36:327-331